A Phase 3 interventional study of Standard 6-month treatment regimen and High dose Rifampicin (25mg/Kg) in Tuberculosis, Pulmonary, Drug Sensitive, sponsored by Tuberculosis Research Centre, India. Recruiting at 15 sites in India. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Tuberculosis Research Centre, India · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing rifampin in Tuberculosis, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Rifampin · Tuberculosis, Pulmonary.
Among the 19 studies testing rifampin in Tuberculosis, Pulmonary, this one has the largest planned enrollment, is the only one that started in 2026, is one of 4 in phase 3, and was the 19th registered.
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
Browse Tuberculosis, Pulmonary studies →3 of the 19 studies testing rifampin in Tuberculosis, Pulmonary are open now, in 8 countries. Recruiting first, the newest first:
Michael Hoelscher · Sites in Gabon, Malawi, Mozambique and 3 more countries
Ages 18–65
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–85
By country, each count listing its studies:
Rifampin: first FDA approval 1971 (RIFADIN). What it is approved for, and how studies give it, is on its page →
Of the 47 Tuberculosis, Pulmonary studies recruiting now, 22 (47%) set no upper age limit and 21 (45%) stop at 75 or younger; 12 take children under 18; 7 take healthy volunteers.
This study: 14 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 134 across the 19 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Tuberculosis Research Centre, India is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Tuberculosis Research Centre, India has 5 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
1 of the studies testing rifampin in Tuberculosis, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05807399Michael HoelscherPanACEA - STEP2C -01 | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing rifampin in Tuberculosis, Pulmonary, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
320 studies on the registry are indexed under Tuberculosis, Pulmonary; 72 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 147 across 228 interventional studies indexed under Tuberculosis, Pulmonary.
Browse Tuberculosis, Pulmonary studies →Tuberculosis Research Centre, India is the lead sponsor of 15 studies on the registry; 4 are open to participants now.
Compared within Tuberculosis, Pulmonary, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tuberculosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol
Drug: High dose Rifampicin (25mg/Kg)
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol
Drug: High dose Rifampicin (25mg/Kg)
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.
Drug: High dose Rifamipicn (25mg/Kg) & Levofloxacin
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol
Drug: Standard 6-month treatment regimen
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol
Drug page: Rifampin
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.
Drug page: Rifampin
Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Time frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Proportion of patients with grade 3 or 4 adverse drug reactions.
Time frame: Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Time frame: Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Time frame: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Time frame: At 1st Month
The cost effectiveness of different treatment regimens
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.
Time frame: Through treatment completion, an average of 24 weeks
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes
Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rifampin
Tuberculosis Research Centre, India